Diarylpropionitrile

Diarylpropionitrile (also known as DPN) is a synthetic, nonsteroidal estrogen that is primarily used in scientific research. It is specifically a selective ERβ agonist, and has no affinity for ERα. DPN was first described in 2000 and was the first selective ERβ agonist to be discovered.

Pharmacology

DPN acts as a selective agonist of ERβ, one of two main types of estrogen receptor. It shows no affinity for ERα. The selectivity of DPN for ERβ over ERα is about 70-fold. The compound has been found to possess potent estrogenic activity in various in vitro and in vivo assays.

Chemistry

DPN is a synthetic compound and is not found in nature. It is a member of the class of compounds known as phenols, which are aromatic compounds that contain a phenolic hydroxyl group. DPN is also a nitrile, which is a compound that contains a cyano functional group (-C≡N).

Research

DPN has been used in scientific research to study the function of ERβ and its potential roles in disease. It has been found to have anti-inflammatory, neuroprotective, and antidepressant-like effects in animal research, among other actions. DPN has also been used to study the potential therapeutic benefits of selective ERβ activation in various conditions, including neurodegenerative diseases, depression, and cancer.

See also

• List of estrogen agonists
• List of phenols

File:WHO Rod.svg This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia